OTC · Shell Companies

Mentari Therapeutics, Inc. (MTRI) Stock Price & Fundamentals

$19.87 +6.83% OTC: MTRI Financial Services

Data as of Nov 16, 2026 (intraday, delayed) · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)

Operating within the United States, Metro Inc. specializes in the information security and education sectors.

Valuation

MetricValue
Price$19.87
Market Cap$10.92M
P/E Ratio0.00
P/B Ratio4.60
P/S Ratio—
EPS (TTM)−$3.12
52-Week High$19.87
52-Week Low$0.01
Dividend Yield—

Financials & Margins

MetricValue
ROE-1300.00%
ROA-433.33%
ROCE—
Gross Margin—
Operating Margin—
Net Margin—
Debt/Equity0.00
Current Ratio1.50

Mentari Therapeutics, Inc. key facts

Points to check

  • Net income was negative in each of the last 5 fiscal years (2022–2026).
  • Return on equity was negative in each of the last 3 fiscal years (2026: -100.0%).

Computed by rule from the reported figures on this page. A description of the numbers, not advice.

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
GTENGores Holdings X, Inc. $10.44 -0.05% 117.02 $470.36M 0.00%
BRK.BBerkshire Hathaway Inc. New $583.34 +1.41% 16.29 $1.25T 0.00%
JPMJP Morgan Chase & Co. $338.21 -2.31% 13.89 $898.15B 1.99%
VVisa Inc. $426.46 +0.16% 34.66 $795.69B 0.66%
MAMastercard Incorporated $661.71 +0.08% 34.24 $576.47B 0.56%
BACBank of America Corporation $50.08 -1.84% 11.87 $345.56B 2.53%
HSBCHSBC Holdings, plc $88.21 -1.57% 12.84 $302.17B 2.21%
MSMorgan Stanley $185.57 -2.66% 14.16 $292.70B 2.56%

Quarterly Results — Last 8 Quarters (USD millions)

MetricSep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Sep '26
Sales$1.0M$1.0M$1.0M—$1.0M$1.0M——
Net Profit−$2.0M−$3.0M−$2.0M−$6.0M−$2.0M−$2.0M−$3.0M−$2.0M
EPS−$2.71−$3.64−$1.94−$0.43−$0.44−$0.51−$0.73−$0.42

Annual Financials (USD)

Metric20222023202420252026
Revenue$1.0M$4.0M$5.0M$5.0M—
Operating Profit−$19.0M−$8.0M———
Net Profit−$19.0M−$8.0M−$8.0M−$8.0M−$13.0M
EPS−$33.17−$3.25−$20.14−$8.36−$3.12
Op Margin-1707.0%-192.0%———

MTRI fundamentals by fiscal year

Pick a measure to chart 7 fiscal years (2020–2026) from the company’s annual statements. Operating margin is not shown for banks, insurers and other financial companies. Free cash flow is not shown for banks, insurers and other financial companies.

MTRI revenue, fiscal 2020–2026 (USD)Revenue was $2 million in 2021 and $5 million in 2025.$0$2M$4M$6M2020202120222023202420252026n/a2020: no figure on file2021: $2M2022: $1M2023: $4M2024: $5M2025: $5Mn/a2026: no figure on file$5M

Total revenue reported for each fiscal year.

Show the numbers
Revenue (USD), by fiscal year
Fiscal year2020202120222023202420252026
Revenue—$2M$1M$4M$5M$5M—
MTRI net income, fiscal 2020–2026 (USD)Net income was −$9 million in 2020 and −$13 million in 2026. Below zero in 2020, 2021, 2022, 2023, 2024, 2025, 2026.−$20M−$15M−$10M−$5M$020202021202220232024202520262020: −$9M2021: −$10M2022: −$19M2023: −$8M2024: −$8M2025: −$8M2026: −$13M−$13M

Net income (profit after all costs, interest and tax) for each fiscal year; a bar below the zero line is a net loss.

Show the numbers
Net income (USD), by fiscal year
Fiscal year2020202120222023202420252026
Net income−$9M−$10M−$19M−$8M−$8M−$8M−$13M
MTRI net margin, fiscal 2020–2026Net margin was -500.0% in 2021 and -160.0% in 2025. Below zero in 2021, 2023, 2024, 2025.−600%−400%−200%0%2020202120222023202420252026n/a2020: no figure on fileNet margin 2021: −500.0%n/a2022: no figure on fileNet margin 2023: −200.0%Net margin 2024: −160.0%Net margin 2025: −160.0%n/a2026: no figure on file−160.0%

Net income as a percentage of revenue, by fiscal year.

Show the numbers
Net margin (per cent), by fiscal year
Fiscal year2020202120222023202420252026
Net margin—−500.0%—−200.0%−160.0%−160.0%—
MTRI return on equity, fiscal 2020–2026Return on equity was -64.3% in 2020 and -100.0% in 2026. Below zero in 2020, 2021, 2022, 2023, 2024, 2025, 2026.−300%−200%−100%0%2020202120222023202420252026Return on equity 2020: −64.3%Return on equity 2021: −166.7%Return on equity 2022: −271.4%Return on equity 2023: −88.9%Return on equity 2024: −66.7%Return on equity 2025: −88.9%Return on equity 2026: −100.0%−100.0%

Net income as a percentage of shareholders’ equity, by fiscal year.

Show the numbers
Return on equity (per cent), by fiscal year
Fiscal year2020202120222023202420252026
Return on equity−64.3%−166.7%−271.4%−88.9%−66.7%−88.9%−100.0%
MTRI eps, fiscal 2020–2026 (USD per share)EPS was −$1.71 in 2020 and −$3.12 in 2026. Below zero in 2020, 2021, 2022, 2023, 2024, 2025, 2026.−$40−$30−$20−$10$020202021202220232024202520262020: −$1.712021: −$37.962022: −$33.172023: −$3.252024: −$20.142025: −$8.362026: −$3.12−$3.12

Earnings per share for each fiscal year.

Show the numbers
EPS (USD per share), by fiscal year
Fiscal year2020202120222023202420252026
EPS−$1.71−$37.96−$33.17−$3.25−$20.14−$8.36−$3.12

Balance Sheet (USD)

Metric20222023202420252026
Total Assets$13.0M$14.0M$12.0M$16.0M$3.0M
Total Liabilities$4.0M$2.0M$3.0M$2.0M$2.0M
Cash$6.0M$9.0M$7.0M$11.0M$11.0M
Borrowings—————

Cash Flow (USD)

Metric20222023202420252026
Operating Cash Flow−$16.0M−$7.0M−$7.0M−$8.0M−$9.0M
Investing Cash Flow−$1.0M−$1.0M$0——
Financing Cash Flow$15.0M$11.0M$5.0M$12.0M$0
Net Cash Flow−$1.0M$3.0M−$2.0M$4.0M−$9.0M
Free Cash Flow−$16.0M−$7.0M−$7.0M−$8.0M−$9.0M

Efficiency Ratios (fiscal years)

Payable days and the cash conversion cycle need a trade-payables line, which these statements do not carry. Working-capital ratios and ROCE are left out for banks, insurers and other financial companies.

Metric20222023202420252026
Asset Turnover0.08×0.29×0.42×0.31×—
ROE %-271.4%-88.9%-66.7%-88.9%-100.0%

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-195.51%
Quick Ratio1.00
Interest Coverage—
Return 1Y2.76%
Return 3Y-75.91%
Return 5Y-99.78%

Filings & documents

Mentari Therapeutics, Inc. (MTRI) reports filed with the US Securities and Exchange Commission, newest first. SEC CIK 0001728328. Links open sec.gov.

Annual reports (10-K)

Latest: 10-K for fiscal 2026 (period ended 30 Jun 2026), filed 9 Sep 2026. Document · Filing index

3 amended annual reports are listed on EDGAR.

Quarterly reports (10-Q)

Labelled by the quarter's period end.

Recent events (8-K)

  • Material agreement; Acquisition or disposition completed; Results of operations; Unregistered sale of equity; Change to security holder rights; Change in control; Director/officer change; Charter or bylaw amendment; Code of ethics change; Shell company status change8-KPress release (EX-99.1)
  • Regulation FD disclosure8-K
  • Charter or bylaw amendment; Shareholder vote results; Other events8-K
  • Regulation FD disclosure8-K
  • Regulation FD disclosure8-K

Proxy statements (DEF 14A)

Source: SEC EDGAR, checked 16 Nov 2026. All filings on SEC EDGAR

Latest News

Mentari Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire · Nov 9, 2026 Mentari Therapeutics Announces Closing of Merger with InMed Pharmaceuticals and Previously Announced $490 Million Financing GlobeNewswire · Nov 9, 2026 InMed Pharmaceuticals Completes Closing of Merger with Mentari Therapeutics PR Newswire · Nov 6, 2026 InMed Announces Expected Closing of Merger and Commencement of Trading on Nasdaq Under the Name "Mentari Therapeutics, Inc." and Ticker Symbol "MTRI" TMX Newsfile · Nov 5, 2026

About Mentari Therapeutics, Inc.

Operating within the United States, Metro Inc. specializes in the information security and education sectors. The company provides a comprehensive suite of security solutions, encompassing information security and privacy, physical security, investigative services, and computer forensics. Furthermore, Metro Inc. offers a diverse range of e-learning programs, including online education in cybersecurity, anti-money laundering compliance, computer crime investigation, and digital forensics. It also provides specialized training for electrical linemen and Medicare services. Beyond its digital offerings, the company delivers traditional classroom instruction, consulting services for adult learning initiatives, and applications for developing online educational content. Metro Inc. also markets SecuScan, a proprietary security product that facilitates both external and internal scanning solutions for small, medium, and large enterprises. Additionally, it specializes in creating dynamic multimedia websites that feature video, advanced animation, and interactive elements. Established in 2004, Metro Inc. is headquartered in Southport, North Carolina.

Mentari Therapeutics, Inc. is headquartered in US.

Mentari Therapeutics, Inc. (MTRI) stock trades at $19.87 with a market capitalization of $10.92M. The stock is valued at price-to-book of 4.60. Over the past 52 weeks the stock has ranged between $0.01 and $19.87, and currently trades at or near its 52-week high.

On profitability, Mentari Therapeutics, Inc. generates a return on equity (ROE) of -1300.00% (negative, reflecting a net loss).

Official website: www.bullzisecurity.com

Mentari Therapeutics, Inc. by the numbers, 2020–2026

Compounded, revenue has grown —% a year over five years, 71.0% over three, 0.0% over the last twelve months. The net loss widened from −$9.0M in 2020 to −$13.0M in 2026.

On a trailing twelve-month basis to Sep '26, revenue is — and net profit −$9.0M.

Cash on hand is $11.0M, cash from operations was −$9.0M in the latest year, positive in 0 of the last 7.

Return on equity has averaged -123.2% over five years, and was -100.0% in the most recent year.

The share price itself has compounded at -70.6% a year over five years, -41.5% over three, -10.3% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Mentari Therapeutics, Inc. (MTRI) — frequently asked questions

What is Mentari Therapeutics, Inc. (MTRI) stock price today?

Mentari Therapeutics, Inc. (MTRI) is currently trading at $19.87, up 6.83% today.

What is MTRI return on equity (ROE)?

Mentari Therapeutics, Inc.'s return on equity (ROE) is -1300.00%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.

What is Mentari Therapeutics, Inc.'s market cap?

Mentari Therapeutics, Inc. has a market capitalization of $10.92M.

How much debt does MTRI carry?

Mentari Therapeutics, Inc. has a debt-to-equity ratio of 0.00. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.

What sector is MTRI in?

Mentari Therapeutics, Inc. is classified under Financial Services, in the Shell Companies industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.

Which exchange is MTRI listed on?

Mentari Therapeutics, Inc. trades on OTC under the ticker MTRI.

What is MTRI's 52-week range?

Over the last year Mentari Therapeutics, Inc. has traded between $0.01 and $19.87.

Related Financial Services Stocks

GTEN Gores Holdings X, Inc. $10.44 -0.05% BRK.B Berkshire Hathaway Inc. New $583.34 +1.41% JPM JP Morgan Chase & Co. $338.21 -2.31% V Visa Inc. $426.46 +0.16% MA Mastercard Incorporated $661.71 +0.08% BAC Bank of America Corporation $50.08 -1.84% HSBC HSBC Holdings, plc $88.21 -1.57% MS Morgan Stanley $185.57 -2.66% RY Royal Bank Of Canada $199.53 -1.37% GS Goldman Sachs Group, Inc. (The) $891.54 -2.73% WFC Wells Fargo & Company $84.85 -1.39% MUFG Mitsubishi UFJ Financial Group, Inc. $21.19 -2.93%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)Exxon Mobil (XOM)

Screens MTRI currently matches

On the figures above, Mentari Therapeutics, Inc. passes the filters for 3 of our ready-made screens, among them Day Gainers Stocks, Debt Free Stocks Under $100, Nano Cap Stocks. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.

Day Gainers StocksDebt Free Stocks Under $100Nano Cap Stocks

Related stock screens

High ROE Financial Services StocksLow P/E Financial Services StocksHigh Net Margin Financial Services StocksDividend Financial Services StocksLow Debt Financial Services StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.